Abstract

The platelet membrane glycoprotein IIb-IIIa complex (GPIIb-IIIa) recognizes peptides containing the amino acid sequence Arg-Gly-Asp, a sequence present at two locations in the alpha chain of fibrinogen. GPIIb-IIIa also interacts with peptides containing the carboxyl-terminal 10-15 residues of the fibrinogen gamma chain. We found that the alpha chain tetrapeptide, Arg-Gly-Asp-Ser (RGDS), and the gamma chain peptide, Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val (LGGAKQAG-DV), each inhibited fibrinogen binding to ADP-stimulated platelets with Ki values of 15.6 +/- 2.7 and 46.2 +/- 8.2 microM, respectively. Furthermore, the inhibitory effect of the peptides was additive, indicating that they interact with GPIIb-IIIa in a mutually exclusive manner. Mutually exclusive binding suggests that either the alpha and gamma chain peptides bind to identical or overlapping sites on the GPIIb-IIIa complex or that one peptide induces a change in the complex that excludes the other. To differentiate between these possibilities, we compared the ability of RGDS and LGGAKQAGDV to inhibit the binding of fibrinogen and two GPIIb-IIIa complex-specific monoclonal antibodies, A2A9 and PAC-1, to ADP-stimulated platelets. A2A9 and PAC-1 appear to bind to different sites on GPIIb-IIIa because A2A9 binds to both stimulated and unstimulated platelets while PAC-1 only binds to stimulated platelets. RGDS specifically inhibited fibrinogen and PAC-1 binding with nearly identical Ki values of 15.6 +/- 2.7 and 20.2 +/- 3.5 microM, respectively. In contrast, LGGAKQAGDV had a differential effect on fibrinogen and PAC-1 binding, inhibiting PAC-1 binding with a Ki of 116.1 +/- 12.9 microM and fibrinogen binding with a Ki of 46.2 +/- 8.2 microM (p less than 0.005). Furthermore, while RGDS had no effect on the binding of the monoclonal antibody A2A9, LGGAKQAGDV was a partial inhibitor of A2A9 binding to activated platelets. These results suggest that the bindings sites for RGDS and LGGAKQAGDV are spatially distinct. They also suggest that ligand-induced changes in GPIIb-IIIa conformation are likely to be responsible for the mutually exclusive nature of alpha and gamma chain peptide binding.

Highlights

  • From the $Hematology-OncologySection and Department of Medicine, University of Pennsylvania School of Medicine, Philadelwhia.Pennsvluania. 19104 and the Dewartmentsof Whemistry and IIBiology, Memphis State University, Memphk, Tennessee38152

  • Gly-Asp-Ser (RGDS), and the y chain peptide, Leu- of this family is its interaction with proteins and peptides

  • To differentiate between these possibilities, we compared the abilityof RGDS and LGGAKQAGDV to inhibit the binding of fibrinogen and two GPIIb-IIIa complex-specific monoclonal antibodies, A2A9 and tides containing this sequence inhibit the binding of these proteins to activated platelets [4, 8,9,10]

Read more

Summary

Interaction of Fibrinogen with Its Platelet Receptor

DIFFERENTIALEFFECTS OF O( AND y CHAIN FIBRINOGEN PEPTIDES ON THE GLYCOPROTEIN IIb-IIIa COMPLEX*. Exclusive binding suggests that either the a and y chain peptides bindto identical or overlapping siteosn the GPIIb-IIIacomplex or thaot ne peptide induces a change in the complex that excludes the other To differentiate between these possibilities, we compared the abilityof RGDS and LGGAKQAGDV to inhibit the binding of fibrinogen and two GPIIb-IIIa complex-specific monoclonal antibodies, A2A9 and tides containing this sequence inhibit the binding of these proteins to activated platelets [4, 8,9,10]. Hotoaffinity labeling experiments using modified Arg-Gly-Aspand y chain peptides suggest that the peptides interact with GPIIb-IIIa at separate sites[15].To resolve this antibody A2A9, LGGAKQAGDV was a partial inhibi- question, we compared the ability of each type of peptide to tor of A2A9 binding to activated platelets.

EXPERIMENTAL PROCEDURES
RESULTS
RGDS RGDS
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.